Improved outcomes over time and higher mortality in CMV
seropositive allogeneic stem cell transplantation patients with
COVID-19; An infectious disease working party study from the
European Society for Blood and Marrow Transplantation registry

J 2023

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

LJUNGMAN, Per, Gloria TRIDELLO, Jose Luis PINANA, Fabio CICERI, Henrik SENGELOEV et. al.

Basic information

Original name

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Authors

LJUNGMAN, Per (guarantor), Gloria TRIDELLO, Jose Luis PINANA, Fabio CICERI, Henrik SENGELOEV, Alexander KULAGIN, Stephan MIELKE, Zeynep Arzu YEGIN, Matthew COLLIN, Sigrun EINARDOTTIR, Sophie Ducastelle LEPRETRE, Johan MAERTENS, Antonio CAMPOS, Elisabetta METAFUNI, Herbert PICHLER, František FOLBER (203 Czech Republic, belonging to the institution), Carlos SOLANO, Emma NICHOLSON, Meltem Kurt YUEKSEL, Kristina CARLSON, Beatriz AGUADO, Caroline BESLEY, Jenny BYRNE, Immaculada HERAS, Fiona DIGNAN, Nicolaus KROEGER, Christine ROBIN, Anjum KHAN, Stig LENHOFF, Anna GRASSI, Veronika DOBSINSKA, Nuno MIRANDA, Maria-Jose JIMENEZ, Ipek YONAL-HINDILERDEN, Keith WILSON, Dina AVERBUCH, Simone CESARO, Alienor XHAARD, Nina KNELANGE, Jan STYCZYNSKI, Malgorzata MIKULSKA and de la Camara RAFAEL

Edition

Frontiers in immunology, LAUSANNE, Frontiers Media S.A. 2023, 1664-3224

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.300 in 2022

RIV identification code

RIV/00216224:14110/23:00130694

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3389/fimmu.2023.1125824

UT WoS

000953835700001

Keywords in English

COVID-19; allogeneic; stem cell transplantation; CMV; risk factors

Abstract

V originále

IntroductionCOVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. MethodsThis study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. ResultsThe median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022. DiscussionAlthough the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.

Citovat

LJUNGMAN, Per, Gloria TRIDELLO, Jose Luis PINANA, Fabio CICERI, Henrik SENGELOEV, Alexander KULAGIN, Stephan MIELKE, Zeynep Arzu YEGIN, Matthew COLLIN, Sigrun EINARDOTTIR, Sophie Ducastelle LEPRETRE, Johan MAERTENS, Antonio CAMPOS, Elisabetta METAFUNI, Herbert PICHLER, František FOLBER, Carlos SOLANO, Emma NICHOLSON, Meltem Kurt YUEKSEL, Kristina CARLSON, Beatriz AGUADO, Caroline BESLEY, Jenny BYRNE, Immaculada HERAS, Fiona DIGNAN, Nicolaus KROEGER, Christine ROBIN, Anjum KHAN, Stig LENHOFF, Anna GRASSI, Veronika DOBSINSKA, Nuno MIRANDA, Maria-Jose JIMENEZ, Ipek YONAL-HINDILERDEN, Keith WILSON, Dina AVERBUCH, Simone CESARO, Alienor XHAARD, Nina KNELANGE, Jan STYCZYNSKI, Malgorzata MIKULSKA and de la Camara RAFAEL. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Frontiers in immunology. LAUSANNE: Frontiers Media S.A., 2023, vol. 14, March 2023, p. 1-11. ISSN 1664-3224. Available from: https://dx.doi.org/10.3389/fimmu.2023.1125824.

@article{2279446,
   author = {Ljungman, Per and Tridello, Gloria and Pinana, Jose Luis and Ciceri, Fabio and Sengeloev, Henrik and Kulagin, Alexander and Mielke, Stephan and Yegin, Zeynep Arzu and Collin, Matthew and Einardottir, Sigrun and Lepretre, Sophie Ducastelle and Maertens, Johan and Campos, Antonio and Metafuni, Elisabetta and Pichler, Herbert and Folber, František and Solano, Carlos and Nicholson, Emma and Yueksel, Meltem Kurt and Carlson, Kristina and Aguado, Beatriz and Besley, Caroline and Byrne, Jenny and Heras, Immaculada and Dignan, Fiona and Kroeger, Nicolaus and Robin, Christine and Khan, Anjum and Lenhoff, Stig and Grassi, Anna and Dobsinska, Veronika and Miranda, Nuno and Jimenez, MariaandJose and YonalandHindilerden, Ipek and Wilson, Keith and Averbuch, Dina and Cesaro, Simone and Xhaard, Alienor and Knelange, Nina and Styczynski, Jan and Mikulska, Malgorzata and Rafael, de la Camara},
   article_location = {LAUSANNE},
   article_number = {March 2023},
   doi = {http://dx.doi.org/10.3389/fimmu.2023.1125824},
   keywords = {COVID-19; allogeneic; stem cell transplantation; CMV; risk factors},
   language = {eng},
   issn = {1664-3224},
   journal = {Frontiers in immunology},
   title = {Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry},
   url = {https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125824/full},
   volume = {14},
   year = {2023}
}

TY  - JOUR
ID  - 2279446
AU  - Ljungman, Per - Tridello, Gloria - Pinana, Jose Luis - Ciceri, Fabio - Sengeloev, Henrik - Kulagin, Alexander - Mielke, Stephan - Yegin, Zeynep Arzu - Collin, Matthew - Einardottir, Sigrun - Lepretre, Sophie Ducastelle - Maertens, Johan - Campos, Antonio - Metafuni, Elisabetta - Pichler, Herbert - Folber, František - Solano, Carlos - Nicholson, Emma - Yueksel, Meltem Kurt - Carlson, Kristina - Aguado, Beatriz - Besley, Caroline - Byrne, Jenny - Heras, Immaculada - Dignan, Fiona - Kroeger, Nicolaus - Robin, Christine - Khan, Anjum - Lenhoff, Stig - Grassi, Anna - Dobsinska, Veronika - Miranda, Nuno - Jimenez, Maria-Jose - Yonal-Hindilerden, Ipek - Wilson, Keith - Averbuch, Dina - Cesaro, Simone - Xhaard, Alienor - Knelange, Nina - Styczynski, Jan - Mikulska, Malgorzata - Rafael, de la Camara
PY  - 2023
TI  - Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
JF  - Frontiers in immunology
VL  - 14
IS  - March 2023
SP  - 1-11
EP  - 1-11
PB  - Frontiers Media S.A.
SN  - 16643224
KW  - COVID-19
KW  - allogeneic
KW  - stem cell transplantation
KW  - CMV
KW  - risk factors
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125824/full
N2  - IntroductionCOVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. MethodsThis study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. ResultsThe median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022. DiscussionAlthough the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.
ER  -

LJUNGMAN, Per, Gloria TRIDELLO, Jose Luis PINANA, Fabio CICERI, Henrik SENGELOEV, Alexander KULAGIN, Stephan MIELKE, Zeynep Arzu YEGIN, Matthew COLLIN, Sigrun EINARDOTTIR, Sophie Ducastelle LEPRETRE, Johan MAERTENS, Antonio CAMPOS, Elisabetta METAFUNI, Herbert PICHLER, František FOLBER, Carlos SOLANO, Emma NICHOLSON, Meltem Kurt YUEKSEL, Kristina CARLSON, Beatriz AGUADO, Caroline BESLEY, Jenny BYRNE, Immaculada HERAS, Fiona DIGNAN, Nicolaus KROEGER, Christine ROBIN, Anjum KHAN, Stig LENHOFF, Anna GRASSI, Veronika DOBSINSKA, Nuno MIRANDA, Maria-Jose JIMENEZ, Ipek YONAL-HINDILERDEN, Keith WILSON, Dina AVERBUCH, Simone CESARO, Alienor XHAARD, Nina KNELANGE, Jan STYCZYNSKI, Malgorzata MIKULSKA and de la Camara RAFAEL. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. \textit{Frontiers in immunology}. LAUSANNE: Frontiers Media S.A., 2023, vol.~14, March 2023, p.~1-11. ISSN~1664-3224. Available from: https://dx.doi.org/10.3389/fimmu.2023.1125824.

Detailed Information on Publication Record